Next Article in Journal
Multi-Person Action Recognition Based on Millimeter-Wave Radar Point Cloud
Previous Article in Journal
Study on Denoising Method of Weld Defect Signal Based on SSA-VMD-WPD
Previous Article in Special Issue
Efficacy and Safety Assessment of Topical Omega Fatty Acid Product in Experimental Model of Irritant Contact Dermatitis: Randomized Controlled Trial
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Efficacy and Tolerability of a Microneedling Device Plus Exosomes for Treating Melasma

by
Ilaria Proietti
1,†,
Chiara Battilotti
1,*,†,
Francesca Svara
1,†,
Carlotta Innocenzi
1,
Alessandra Spagnoli
2 and
Concetta Potenza
1
1
Dermatology Unit “Daniele Innocenzi”, “A. Fiorini” Hospital, Via Firenze, 1, 04019 Terracina, Italy
2
Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Appl. Sci. 2024, 14(16), 7252; https://doi.org/10.3390/app14167252 (registering DOI)
Submission received: 12 July 2024 / Revised: 31 July 2024 / Accepted: 16 August 2024 / Published: 17 August 2024
(This article belongs to the Special Issue Cosmetics Ingredients Research)

Abstract

Melasma is a challenging skin condition which involves both structural and functional skin alterations. Despite the availability of various treatment options, the management remains complex. This is the first study to investigate topical application of Rosa Damascena stem cell exosomes when used concomitantly with microneedling in women and men with facial melasma. We recruited 20 subjects with Fitzpatrick skin types I-III, exhibiting melasma of varying severity. The modified Melasma Area and Severity Index (mMASI) and Global Aesthetic Improvement Scale (GAIS) were utilized to evaluate treatment response. The treatment protocol involved microneedling followed by exosome application over four or five sessions, at 4-week intervals. Ninety percent of subjects demonstrated a significant improvement in mMASI scores, while only 10% showed no change. GAIS assessment further supports overall improvement, with just 10% categorized as “not changed”. Tolerability was favorable, with mild, transient side effects. Our findings suggest promising outcomes with this combined therapy, underscoring its potential as a safe and effective approach for treating melasma, particularly in severe and moderate cases. However, further research with larger sample sizes and control arms is warranted to validate these findings and explore long-term efficacy.
Keywords: Melasma; exosomes; microneedling; mMASI; GAIS Melasma; exosomes; microneedling; mMASI; GAIS

Share and Cite

MDPI and ACS Style

Proietti, I.; Battilotti, C.; Svara, F.; Innocenzi, C.; Spagnoli, A.; Potenza, C. Efficacy and Tolerability of a Microneedling Device Plus Exosomes for Treating Melasma. Appl. Sci. 2024, 14, 7252. https://doi.org/10.3390/app14167252

AMA Style

Proietti I, Battilotti C, Svara F, Innocenzi C, Spagnoli A, Potenza C. Efficacy and Tolerability of a Microneedling Device Plus Exosomes for Treating Melasma. Applied Sciences. 2024; 14(16):7252. https://doi.org/10.3390/app14167252

Chicago/Turabian Style

Proietti, Ilaria, Chiara Battilotti, Francesca Svara, Carlotta Innocenzi, Alessandra Spagnoli, and Concetta Potenza. 2024. "Efficacy and Tolerability of a Microneedling Device Plus Exosomes for Treating Melasma" Applied Sciences 14, no. 16: 7252. https://doi.org/10.3390/app14167252

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop